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Abstract 
Alliance Against Cancer (ACC) was established in Rome in 2002 as a consortium of six Italian comprehensive cancer 
centers (Founders). The aims of ACC were to promote a network among Italian oncologic institutions in order to 
develop specific, advanced projects in clinical and translational research. During the following years, many additional 
full and associate members joined ACC, that presently includes the National Institute of Health, 17 research-oriented 
hospitals, scientific and patient organizations. Furthermore, in the last three years ACC underwent a reorganiza-
tion process that redesigned the structure, governance and major activities. The present goal of ACC is to achieve 
high standards of care across Italy, to implement and harmonize principles of modern personalized and precision 
medicine, by developing cost effective processes and to provide tailored information to cancer patients. We herein 
summarize some of the major initiatives that ACC is currently developing to reach its goal, including tumor genetic 
screening programs, establishment of clinical trial programs for cancer patients treated in Italian cancer centers, facili-
tate their access to innovative drugs under development, improve quality through an European accreditation process 
(European Organization of Cancer Institutes), and develop international partnerships. In conclusion, ACC is a growing 
organization, trying to respond to the need of networking in Italy and may contribute significantly to improve the 
way we face cancer in Europe.
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Background
Cancer care is a major health problem worldwide. Many 
countries have recognized that more effective preven-
tion, diagnosis and treatment of cancer require substan-
tial improvements in the coordination of clinical centers 
and new initiatives to improve our understanding of both 
clinical and biological aspects of cancer. Prerequisites 
for success include a sufficient critical mass of infra-
structures for cancer care and research, the existence of 
qualified molecular profiling laboratories and a sound 
scientific international background and reputation in 
cancer research. To address these issues, various initia-
tives are being developed in Europe and/or worldwide. As 
an example, the basic idea behind Cancer Core Europe, 
a consortium including six cancer centers from differ-
ent European Countries (EU), is to build a virtual cancer 
Institute that allows to increase research coordination, 
emphasis on the development of personalized oncology 
to apply state of the art technology to patient care, the 
creation of an appropriate legal and ethical framework to 
encourage collaboration between all stakeholders of can-
cer continuum [1–3]. The WIN Consortium represents 
a further example of global collaboration among cancer 
centers, life science and biotech organizations, pharma-
ceutical and technology companies, health plans, and 
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patient advocacy groups coming together from four dif-
ferent continents [4]. This consortium offers an opportu-
nity to make an impact on personalized cancer therapy 
across the globe by increasing the number of patients, 
whose malignant cells have been profiled with cutting 
edge genomic and transcriptomic technologies, to be 
recruited to innovative clinical trials and treatment with 
the latest innovative drugs [5]. In this paper, we present 
the approach that is being undertaken in Italy by ACC 
to build up a virtual cancer institute spanning across the 
whole country with the intent to achieve high and uni-
form standards of cancer research and care, with particu-
lar emphasis on personalized cancer therapy based on 
genomic profiling and on innovative clinical trials.
Brief history of ACC
ACC was established in Rome in 2002 as a consortium 
of six Italian comprehensive cancer centers (Founders) 
recognized by the national Ministry of Health (MoH) 
as high standard Institutes for both patient care and 
research (Istituti di Ricovero e Cura a Carattere Scien-
tifico-IRCCS). IRCCS are formally defined by a national 
law stating that they represent institutions of national 
relevance pursuing research, mainly clinical and transla-
tional, and high quality diagnostic and therapeutic pro-
cedures. The aims of ACC were to promote a network 
among Italian oncologic institutions in order to develop 
specific, advanced projects in clinical and translational 
research. With the purpose to generate synergies also 
with other specialties involved in health care, ACC was 
chaired by the President of the National Institute of 
Health. During the first years of activity, ACC developed 
projects in three areas: a) diagnosis and therapy of cancer 
b) basic and clinical oncologic research c) education and 
information in oncology. Within these three areas, some 
innovative ideas were included, like the constitution of 
networks in telepathology, rare cancers, quality of life and 
the molecular classification of solid cancers (genomics 
and proteomics). During the following years, many addi-
tional full and associate members joined ACC, that pres-
ently includes 20 members (Fig. 1). A farsighted idea was 
the inclusion of patients’ associations within the active 
members and in the assembly of this association, a situ-
ation that is now becoming usual in national and inter-
national associations or initiatives and scientific societies 
for cancer care and research [4, 6]. Thanks to the collabo-
ration with cancer patients organizations, ACC has real-
ized the National Cancer Information Service (SION). 
In its initial configuration, ACC was not organized as an 
official entity according to national laws, a situation that 
consistently limited its activities. For this reason, over the 
last three years ACC underwent a reorganization pro-
cess that redesigned the structure, governance and major 
activities. The President is nominated every five years by 
the Minister of Health among the list of translational sci-
entists selected by the scientific directors of the Founders 
Institutes, while ACC is now a formal legal entity that can 
interact with companies and can apply to national and 
international profit and nonprofit research grants. This is 
in line with the new major commitment of ACC that con-
cerns the translation of research innovation into clinical 
trials and routine clinical practice.
The ACC network has now 20 members, includ-
ing six founders, 12 full and two adherent members 
(Fig. 1), where approximately a total of 3000 scientists are 
involved in translational and clinical research, producing 
publications in peer reviewed international journal for 
21,000 Impact Factor Points/year. A distinguishing fea-
ture is the high emphasis to clinical trials, with more than 
2800 active trials and more than 45,000 patients presently 
enrolled.
Qualifying aspects of ACC and current strategy
The most qualifying elements of this alliance, may be 
considered as follows.
a. Within the ACC consortium, all cancer IRCCS offi-
cially recognized by the Italian MoH are present 
independent on their size and geographical location, 
according to a principle of inclusiveness and equal-
ity. This represents the willingness to establish similar 
standards of care and quality of research across the 
entire country;
b. These centers have recently undergone international 
European Organization of Cancer Institutes (OECI) 
accreditation (see below);
c. ACC does not include only centers dedicated to can-
cer, but also other IRCCS in which other medical 
disciplines (i.e. orthopedics, neurology, dermatology) 
are present. This approach favors the coverage to a 
greater extent of rarer types of cancer such as sarco-
mas, brain tumors, skin cancers etc.;
d. The presence within ACC of the Italian Cancer 
Patients’ Organization (AIMaC) provides a bidirec-
tional information exchange between patients and 
institutes with a continuous stimulus to look after 
patient’s needs;
e. ACC governance allows sustainability of the consor-
tium because each member is providing basic fund-
ing for ACC functioning through its balance.
The main goal of ACC is to achieve high standards of 
care across the country, implement and harmonize prin-
ciples of modern personalized and precision medicine, by 
developing cost effective processes. This will be achieved 
through a defined set of initiatives of efforts in genomic 
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medicine, new clinical trials, quality of cancer care, and 
development of international collaborations at the Euro-
pean and worldwide level.
We herein summarize the major initiatives that cur-
rently characterize ACC.
1. Tumor genetic screening programs. The first step 
of this program was the establishment of the ACC 
Genomics, a group including representatives from 
different ACC members working together to reach 
the following goals: a) to establish a shared strat-
egy among all centers for genomic profiling of can-
cer patients by next generation sequencing of driver 
and actionable mutations; b) to establish network 
genomic profiling programs using quality assurance 
protocols to monitor implementation of new test 
regulations and to stimulate laboratories to improve 
their testing procedures; c) to build up a permanent 
DNA mutation registry of cancer patients treated in 
the participating centers open for consultation to all 
members of the Consortium. Through the collection 
of a high number of DNA profiles, we expect to iden-
tify sufficient patients whose cancers have specific 
genetic alterations to allow their recruitment into 
personalized medicine clinical trials.
2. ACC has recently established working groups (WG) 
for each of the six major cancer types for which there 
is a strong expertise among the network: lung, breast 
and colorectal cancers, melanoma, glioblastoma and 
sarcomas. Each WG includes two members from 
each center, either preclinical or clinician scientists, 
to facilitate the cancer care-translational research 
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Fig. 1 Alliance Against Cancer. The Network of Alliance Against Cancer (ACC) is composed of 20 members, including 6 founders, 10 full members 
and 2 associate members
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continuum. The final goal of these WG is to establish 
clinical trial programs for cancer patients treated in 
Italian cancer centers and to facilitate their access to 
innovative drugs under development. The existence 
of the ACC network and shared governance and the 
existence of common nationally shared regulatory 
rules overcomes some of the hurdles that limits inter-
national studies including countries with different 
rules/regulations [5].
3. European designation and accreditation of cancer 
centers. Presently, OECI has developed the most 
commonly used accreditation program at the Euro-
pean level for cancer centers, with more than 25 
institutions having started the Accreditation and 
Designation procedure (A&D). The OECI A&D pro-
gram includes standards on general management, 
screening and prevention, care, research and on 
patients involvement. Presently all the ACC active 
members at the moment of application (2012) are 
part of this program, meaning that Italy is the only 
European country that has considered essential to 
share an internationally recognized, high quality, 
accreditation system for cancer centers [7].
4. Quality approach to colorectal cancer care. Clinical 
quality can be measured in several manners includ-
ing with audits by specialized teams on selected types 
of cancer. Since this approach can be most accurate 
and reliable, pilot audits have been carried out on 
the procedures employed in some of the ACC cancer 
centers. Given its proven feasibility and the interest-
ing data collected, this methodology will be extended 
to other cancer centers and to other cancer types at 
the national level [8].
5. Facilitate SION improvement and expansion to meet 
the increasing demand for information [9].
International outlook of ACC
ACC is not conceived as a close endeavour including only 
Italian components, but rather as a large Consortium 
born to be engaged in International partnerships. Cur-
rent international activities of ACC can be summarized 
as follows:
1. Sustaining the European area of translational cancer 
research. Transcan is an ERANet project aiming at 
linking translational cancer research funding pro-
grams of EU member states and associated countries. 
Recognizing the strategic importance of this initiative 
and aiming to improve its internationalization, ACC 
decided to be part of the Transcan International con-
sortium and became a funding body of Transcan2 
by devolving part of its budget to financially support 
projects starting from the 2014 call on Tumor Het-
erogeneity [10].
2. ACC has made substantial efforts in the improve-
ment of cancer care at the European level through 
the participation and financial support to Benchcan, 
an OECI project co funded by the Health Programme 
of the European Union [11]. The general objective 
of Benchcan is to benchmark comprehensive cancer 
care and yield best practice examples in a way that 
contributes to improving the quality of interdiscipli-
nary patient treatment. To achieve this, the project 
addresses six specific objectives:
1. To collect, compare and align by consensus for-
mation the standards, recommendations and 
accreditation criteria of comprehensive cancer 
care in selected European countries.
2. To review and refine a benchmarking tool that 
can be applied to comprehensive cancer care 
through interdisciplinary patient treatment.
3. To pilot the benchmark tool with particular 
attention to operations management and best 
clinical practice.
4. To maximize knowledge exchange and shar-
ing of best practice between providers of com-
prehensive cancer care in member states and 
regions.
5. To ensure compatibility of the benchmarking 
tools with existing cancer care resources and 
services.
6. To ensure the sustainability and longer-term 
benefits of the project.
The pilot phase has been already concluded and results 
are under evaluation and reporting.
3. ACC is entering the MD Anderson Sister Institution 
Network Program, a global network of major can-
cer institutions from 23 countries in five continents. 
This partnership involves translational research, drug 
development and clinical trials. The impact of such 
partnership appears of great potential for the devel-
opment of innovative clinical trials, which may ben-
efit considerably from the availability of a large num-
ber of fully characterized patients coupled with the 
strong expertise of MD Anderson in clinical trials. 
In this context, the development of common clini-
cal databases may provide a unique opportunity for a 
strong global clinical partnership.
Conclusions and future developments
Due to current changes in demographic, social and eco-
nomic situation, the development of a strategic approach 
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to improve a cancer research and care agenda represents 
a major challenge for EU countries and worldwide. The 
new configuration and program of ACC represents a con-
sistent opportunity for Italy. Advantages of ACC are that 
collaboration is defined by a legal act, is stable, sustained 
by an annual membership fee of members, supported by 
MoH and not temporarily linked to projects that have a 
definite time lapse. At the same time, each partner main-
tains its operational autonomy and, according to laws, is 
included in regional healthcare plans, while participat-
ing to the development of highly innovative approaches 
to cancer diagnosis and care. Ultimately, this approach 
has the potential to greatly increase the number of early 
clinical trials in Italy and to offer innovative therapies to 
patients all around the country. Another important effect 
of ACC strategic plan on genomics, is the possibility to 
reduce significantly the cost of genomic testing, thus 
making this an opportunity to be applied widely to all 
cancer patients in Italy.
Future developments of ACC programs will include the 
application of genomic approach linked to clinical trials 
to all other major cancer types, with the aim to provide 
access to precision medicine clinical trial to metastatic 
patients unable to be treated successfully with currently 
approved therapeutic regimens. Furthermore, precision 
medicine initiatives within ACC will aim to implement 
integration of genomic platforms with different immuno-
therapy approaches.
In conclusion, ACC is a growing organization, that is 
addressing the need of oncology networking in Italy. 
We foresee that ACC strategy will be a driving force for 
translational and clinical, while contributing significantly 
to the internationalization of Italian oncology and the dif-
fusion of high standard clinical practice in Italy.
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